...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
【24h】

Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients

机译：作为乳腺癌患者骨转移的新型诊断生物标志物循环骨钙蛋白阳性细胞

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current diagnosis of bone metastasis (BM) in breast cancer relies on structural changes of bone that occur only in the advanced stage. A sensitive biomarker for detecting early progression of bone metastasis is urgently required. We performed clinical and preclinical studies to investigate diagnostic value of circulating osteocalcin-positive cells (cOC) in breast cancer bone metastasis. Metastatic breast cancer patients (n = 92) with or without bone metastasis (ie, BM+ or BM-) were enrolled, and cOC were measured at enrollment. Patients were followed up for bone metastasis progression for 18 months. BM+ patients (n = 59) were divided into progressive (PD) or stable disease (SD) groups, based on imaging studies at the end of the 18-month study. The PD group had higher baseline cOC compared with the SD group. Furthermore, higher cOC resulted in reduced BM progression-free survival. Three patients in the BM- group (n = 33) developed new BM during the 18-month study, and these patients had a higher level of baseline cOC compared with the remaining BM- patients. In murine preclinical studies, cOC increased at early time points when micro-metastases were evident only by histology but undetectable by bioluminescence imaging. Also, cOC levels predicted the progression of BM and correlated significantly with BM tumor burden. cOC increased in the early phase of breast cancer BM and can predict BM progression, supporting cOC as a potential novel biomarker. (c) 2020 American Society for Bone and Mineral Research.
机译：目前乳腺癌骨转移（BM）的诊断依赖于仅在晚期发生的骨结构变化。迫切需要一种敏感的生物标志物来检测骨转移的早期进展。我们进行了临床和临床前研究，以探讨循环骨钙素阳性细胞（cOC）在乳腺癌骨转移中的诊断价值。有或无骨转移（即BM+或BM-）的转移性乳腺癌患者（n=92）被纳入研究，并在纳入研究时测量cOC。随访患者18个月的骨转移进展情况。根据18个月研究结束时的影像学研究，BM+患者（n=59）被分为进展期（PD）或稳定期（SD）组。PD组的基线cOC高于SD组。此外，较高的cOC导致BM无进展生存率降低。在为期18个月的研究中，BM组的三名患者（n=33）出现了新的BM，与其他BM组患者相比，这些患者的基线cOC水平更高。在小鼠临床前研究中，cOC在早期时间点增加，此时微转移仅通过组织学表现明显，但通过生物发光成像无法检测到。此外，cOC水平预测BM的进展，并与BM肿瘤负荷显著相关。cOC在乳腺癌BM早期增加，可以预测BM进展，支持cOC作为一种潜在的新生物标记物。（c） 2020年美国骨与矿物研究学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号